Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
Date:2/24/2011

NANJING, China, Feb. 24, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2010 on Tuesday, March 8, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, March 8 at 9 p.m. Beijing/Hong Kong time).To access the conference call, please dial:United States toll-free:

+1.866.831.5605International:

+1.617.213.8851China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:

10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)

400.881.1630 / 400.881.1629Hong Kong:

+852.3002.1672Please ask to be connected to Q4 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 56440566

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.888.286.8010 International:

+1.617.801.6888The passcode for replay participants is: 22405893.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.comIn Nanjing:

Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8811In the United States:

Kate Tellier
Brunswick Group
Tel: 1-212-333-3810In Beijing:
Ruirui Jiang
Brunswick Group
Tel: 86-10-5960-8600In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
2. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
3. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
4. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
8. Simceres Diosmectite API Passes EU-GMP Inspection
9. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
11. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
(Date:4/18/2017)... , April 18, 2017 Research and ... the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast ... ... molecular imaging equipment revenues as well as growth in the ... will provide value to market participants that design and manufacture ...
(Date:4/18/2017)... TAMPA, Fla. , April 18, 2017 WellCare ... Health Plans, Inc. (NYSE: WCG), announced today it will award ... Kentucky to reduce tobacco use and promote smoke-free ... Center for Smoke-Free Policy conference hosted by the University of ... first time WellCare, the state,s largest Medicaid managed care organization, ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... system, has partnered with O2X , an active lifestyle company that provides ... improving the health of firefighters, police offers, first responders, military officers and others ...
(Date:4/21/2017)... Santa Rosa, CA (PRWEB) , ... April 21, ... ... with St. Joseph Health held the much anticipated Regional Primary Care Spring Symposium ... vital role in the local medical community, offering physicians and healthcare providers an ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join the ... festival offers entertainment for everyone — from the avid gardener to the landscape admirer ... high quality event held in a grand venue, and we are certainly looking forward ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in ... bed bug infestations over the 5-year period. In 2015 10% or US$750 million per ... bed bug infested properties. , The health and economic consequences of bed bug ...
Breaking Medicine News(10 mins):